Johnson & Johnson (NYSE:JNJ) Shares Purchased by Hourglass Capital LLC

Hourglass Capital LLC increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.7% during the 1st quarter, HoldingsChannel reports. The fund owned 13,575 shares of the company’s stock after acquiring an additional 100 shares during the quarter. Hourglass Capital LLC’s holdings in Johnson & Johnson were worth $2,406,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. SlateStone Wealth LLC raised its holdings in Johnson & Johnson by 164.4% in the 1st quarter. SlateStone Wealth LLC now owns 22,743 shares of the company’s stock valued at $4,031,000 after buying an additional 14,142 shares during the period. Thoroughbred Financial Services LLC raised its holdings in Johnson & Johnson by 51.1% in the 1st quarter. Thoroughbred Financial Services LLC now owns 38,478 shares of the company’s stock valued at $6,819,000 after buying an additional 13,014 shares during the period. swisspartners Ltd. raised its holdings in Johnson & Johnson by 138.5% in the 1st quarter. swisspartners Ltd. now owns 10,088 shares of the company’s stock valued at $4,825,000 after buying an additional 5,858 shares during the period. Brio Consultants LLC purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $230,000. Finally, Northeast Investment Management raised its holdings in Johnson & Johnson by 0.7% in the 1st quarter. Northeast Investment Management now owns 224,763 shares of the company’s stock valued at $39,835,000 after buying an additional 1,545 shares during the period. Institutional investors and hedge funds own 68.78% of the company’s stock.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $171.79 on Friday. The stock has a 50 day moving average price of $175.41 and a 200 day moving average price of $174.52. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $451.67 billion, a price-to-earnings ratio of 25.01, a price-to-earnings-growth ratio of 3.29 and a beta of 0.59. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.48 earnings per share. Research analysts predict that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JNJ. Citigroup cut their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Raymond James boosted their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Finally, The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $189.89.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.